Platinum Industries will organise a plant visit for investors and analysts at its facility in Palghar, Maharashtra, on Tuesday, September 29, 2026.

The company filed the intimation with stock exchanges on September 24, 2026, pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The visit aims to provide stakeholders with direct access to operational facilities.

Interaction guidelines

During the interaction, the company will refer exclusively to publicly available information. No confidential or unpublished price sensitive information (UPSI) will be shared with participants. The schedule remains subject to change due to unavoidable exigencies.

Details regarding the visit will be made available on the company's official website.

Platinum Industries has scheduled its sixth annual general meeting for September 24, 2026. The agenda features significant capital allocation toward its international expansion and related-party financing arrangements.

The company seeks shareholder approval for a capital investment of ₹ 500 million in Platinum Stabilizers Egypt LLC (PSEL). This infusion supports the establishment of a manufacturing facility in Egypt for PVC stabilizers and other chemical products.

Meeting Logistics and E-Voting

The 6th AGM will be held through Video Conferencing (VC) or Other Audio-Visual Means (OAVM) at 11:00 am IST. The notice was dispatched electronically on September 2, 2026. Shareholders holding equity shares as on the cut-off date of September 17, 2026, are eligible to vote.

Remote e-voting will commence on Monday, September 21, 2026 at 9:00 am and end on Wednesday, September 23, 2026 at 5:00 pm. Bigshare Services Private Ltd facilitates the voting process. Members who cast votes remotely cannot vote again during the AGM.

Related-Party Transactions

The board proposes omnibus approvals for material related-party transactions with two subsidiaries during FY27:

Both PSEL and Platinum Oleo Chemicals Private Limited (POCPL) are wholly or majority-owned subsidiaries. The transactions with PSEL total ₹ 800 million, while those with POCPL also aggregate to ₹ 800 million. The audit committee has recommended these deals, stating they are conducted at arm's length.

Director Loans and Reappointment

Shareholders will vote on special resolutions to grant unsecured loans of up to ₹ 25 crore each to POCPL and Rivadu Lifesciences Private Limited. These loans carry an interest rate of 9% per annum and are repayable on demand. Directors Ms. Parul Krishna Rana and Mr. Krishna Dushyant Rana have declared interests in these respective entities.

Additionally, the meeting will consider the reappointment of Mr. Anup Singh as a director. His proposed remuneration is set at ₹ 70,00,000 for the ensuing term.

What the Numbers Show

The proposed capital expenditure in Egypt represents the largest single component of the related-party transaction approvals. The ₹ 500 million equity infusion accounts for 62.5% of the total ₹ 800 million transaction limit approved for PSEL. This indicates a strategic shift from operational trading flows to heavy asset creation in the African market, funded partly by IPO proceeds and internal accruals.